Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know

Area of Science:

• Oncology
• Dermatology
• Immunotherapy

Background:

• Immune checkpoint inhibitors (ICI) are a significant advancement in cancer therapy.
• Managing ICI-related side effects presents a challenge for clinicians due to their unpredictable nature.
• Dermatologic adverse events are common but often manageable.

Purpose of the Study:

• To comprehensively review dermatologic side effects associated with immune checkpoint inhibitors.
• To categorize these side effects based on ICI subtype and combination therapies.
• To report rare dermatologic adverse events and propose a management strategy.

Main Methods:

• Systematic review of clinical trial data on ICI therapies.
• Inclusion of reported rare case studies of dermatologic side effects.
• Development of a clinical management algorithm for dermatologic adverse events.

Main Results:

• Dermatologic side effects, including rash, pruritus, and vitiligo, are frequent with ICI use.
• The review categorizes side effects by specific ICI agents and treatment combinations.
• Rare but significant dermatologic reactions were identified and documented.

Conclusions:

• Understanding the spectrum of dermatologic side effects is crucial for effective ICI therapy.
• A structured approach to managing these side effects can improve patient outcomes.
• The proposed algorithm aids oncologists in timely and appropriate patient care.